Loading company…
Tvardi Therapeutics develops oral small molecule therapies that target STAT3 for fibrosis-related diseases such as IPF.
Founded in 2017 in Houston, US, Tvardi Therapeutics develops oral small-molecule drugs that target STAT3 for chronic fibrosis, with idiopathic pulmonary fibrosis (IPF) as a main focus. Its revenue model relies on partnerships with pharmaceutical companies and research institutions. In June 2021 the company raised USD 72.42 mn in a Series B round with investors including 683 Capital Management, ArrowMark Partners, Palkon Capital Management and Slate Path Capital. The company was valued at USD 190.51 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in